Phase II randomized open-label trial of the EGFR [epidermal growth factor receptor] tyrosine kinase inhibitor OSI-774 [erlotinib] in combination with paclitaxel and carboplatin prior to surgery in resectable stage IIIA (N2) and IIIB (T4 N2) NSCLC [non-small cell lung cancer]: clinical outcome and biological endpoint trial

Trial Profile

Phase II randomized open-label trial of the EGFR [epidermal growth factor receptor] tyrosine kinase inhibitor OSI-774 [erlotinib] in combination with paclitaxel and carboplatin prior to surgery in resectable stage IIIA (N2) and IIIB (T4 N2) NSCLC [non-small cell lung cancer]: clinical outcome and biological endpoint trial

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 May 2016

At a glance

  • Drugs Carboplatin; Erlotinib; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Apr 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 11 Jan 2008 The expected completion date for this trial is now 1 Sep 2008.
    • 07 Jan 2008 Status changed from suspended to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top